



Vaccine uptake

Vaccine uptake in the Dutch National Immunisation Programme stabilised



Intention towards maternal pertussis vaccination




Immunosurveillance



Dose-schedule
Post vaccination


High antibody concentrations against vaccine types HPV16/18

Overall seroprevalence in Caribbean Netherlands



Meningococcal B disease

Vaccination not recommended
Reassess after 3 years



Meningococcal ACWY disease



14 months
Continue with vaccination



14 years
Implement vaccination in the National Immunisation Programme

Decisions
Ministry of Health

Highlights surveillance
2018 - 2019

Reported adverse events


following immunisation

1,519 reports of 5,208 possible adverse effects

An increase of 9.8% due to introduction of MenACWY vaccination for 14-years-olds

Disease

Measles



Local measles outbreak in low vaccination municipality



Meningococcal W

After an increase since 2015, a decrease or stabilization was seen in almost all age groups in the first six months of 2019



HPV

Recommended to vaccinate




Offer supplemental vaccination to unvaccinated adults up to 26



Herpes Zoster

Recommended Vaccination of elderly people with the new herpes zoster vaccine

According to the Health Council the **new herpes zoster vaccine** cost-effectiveness should not exceed the commonly used reference value of €20,000 per QALY



Pathogen

Incidence of invasive pneumococcal disease

